Literature DB >> 24589397

Patient perspectives on radiation dose.

Joyce Graff1.   

Abstract

People with genetic cancer syndromes have a special interest in imaging. They also have special risk factors with respect to radiation. They need to utilize the potential of imaging while keeping in mind concerns about cumulative radiation exposure. Before imaging, early detection of problems was limited. With imaging, issues can be identified when they are small and a good plan of action can be developed early. Operations can be planned and metastatic cancer avoided. The positive contribution of imaging to the care of these patients can be profound. However, this additional surveillance is not without cost. An average patient with 1 of these syndromes will undergo 100 or more scans in their lifetime. Imaging professionals should be able to describe the risks and benefits of each scan in terms that the patient and the ordering physician can understand to make smart decisions about the ordering of scans. Why CT versus MRI? When are x-ray or ultrasound appropriate, and when are they not? What are the costs and the medical risks for the patient? What value does this picture add for the physician? Is there a way to answer the medical question with a test other than a scan? Medicine is a team sport, and the patient is an integral member of the team.
Copyright © 2014 American College of Radiology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Genetics; lifetime risk; patients as partners; radiation

Mesh:

Year:  2014        PMID: 24589397     DOI: 10.1016/j.jacr.2013.10.008

Source DB:  PubMed          Journal:  J Am Coll Radiol        ISSN: 1546-1440            Impact factor:   5.532


  4 in total

Review 1.  Communicating radiation risk to patients and referring physicians in the emergency department setting.

Authors:  Jeffrey Y Shyu; Aaron D Sodickson
Journal:  Br J Radiol       Date:  2016-01-11       Impact factor: 3.039

Review 2.  The incidental pulmonary nodule in a child. Part 2: Commentary and suggestions for clinical management, risk communication and prevention.

Authors:  Sjirk J Westra; Paul G Thacker; Daniel J Podberesky; Edward Y Lee; Ramesh S Iyer; Shilpa V Hegde; R Paul Guillerman; Maryam Ghadimi Mahani
Journal:  Pediatr Radiol       Date:  2015-02-06

3.  Endolymphatic Sac Tumor Screening and Diagnosis in von Hippel-Lindau Disease: A Consensus Statement.

Authors:  Gautam U Mehta; H Jeffery Kim; Paul W Gidley; Anthony B Daniels; Mia E Miller; Gregory P Lekovic; John A Butman; Russell R Lonser
Journal:  J Neurol Surg B Skull Base       Date:  2021-04-08

Review 4.  Is There a Role for Biomarkers in Surveillance of Pancreatic Neuroendocrine Neoplasms in Von Hippel-Lindau Disease?

Authors:  Myrthe R Naber; Saya Ahmad; Annemarie A Verrijn Stuart; Rachel H Giles; Gerlof D Valk; Rachel S van Leeuwaarde
Journal:  J Endocr Soc       Date:  2021-12-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.